Brazil achieves milestone in eliminating lymphatic filariasis

The World Health Organization (WHO) congratulates Brazil for having eliminated lymphatic filariasis as a public health problem.

Eliminating a disease is a momentous accomplishment that takes unwavering commitment. I congratulate Brazil for its efforts to free its people of the scourge of this painful, disfiguring, disabling and stigmatizing disease. This is another example of the incredible progress we have made against neglected tropical diseases and gives hope to many other nations still fighting against lymphatic filariasis that they too can eliminate this disease."

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General

Lymphatic filariasis, commonly known as elephantiasis, is a debilitating parasitic disease spread by mosquitoes. For centuries, this disease has afflicted millions worldwide, causing pain, chronic, severe swelling, serious disability, and social stigmatization.

Effective country-level investments

Over the past few decades, Brazil has implemented integrated actions to eliminate lymphatic filariasis, including the development of a national plan to fight this disease in 1997, the mass distribution of antiparasitic drugs, vector control activities, and strong surveillance, particularly in the most affected areas. With these efforts, the country achieved the end of disease transmission in 2017.

The elimination of lymphatic filariasis was also one of the goals of the Brasil Saudável program, a multisectoral initiative aimed at ending socially determined diseases with a whole-of-government approach and civil society participation, including the involvement of affected people in the implementation of disease control efforts. The programme was launched in February 2024 by President Luiz Inácio Lula da Silva in a ceremony with the participation of Dr Tedros Adhanom Ghebreyesus, WHO Director-General and Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO) and WHO Regional Director for the Americas. In the post-elimination phase, Brazil, PAHO, and WHO will continue to closely monitor for possible resurgence of infections.

"This milestone is the result of years of dedication, hard work, and collaboration among health workers, researchers, and authorities in Brazil", said Dr Jarbas Barbosa, PAHO Director and WHO Regional Director for the Americas. "Brazil's extensive and unified health system, coupled with solid specialized laboratory expertise and robust surveillance were essential to interrupt the chain of transmission, inspiring other countries to advance towards the elimination of lymphatic filariasis and other neglected tropical diseases".

Global progress

Globally, Brazil joins 19 other countries and territories that have been validated by WHO for having eliminated lymphatic filariasis as a public health problem. These are Malawi and Togo in the African Region; Egypt and Yemen in the Eastern Mediterranean Region; Bangladesh, Maldives, Sri Lanka and Thailand in the South-East Asia Region; and Cambodia, Cook Islands, Kiribati, Lao People's Democratic Republic, Marshall Islands, Niue, Palau, Tonga, Vanuatu, Viet Nam and Wallis and Futuna in the Western Pacific Region.

In the Americas, three endemic countries (Dominican Republic, Guyana, and Haiti) still require mass drug administration to stop transmission and are working to achieve the elimination target.

In addition to being the 20th country to be validated for elimination of lymphatic filariasis as a public health problem, Brazil has also become the 53rd country to have eliminated at least one neglected tropical disease, globally.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Could eating eggs prevent dementia?